China has suspended the import, sale, and use of rivastigmine tartrate capsules manufactured by India’s Sun Pharmaceutical Industries Limited following regulatory violations identified during an inspection, the country’s top drug regulator said.
In a statement released on January 23, the National Medical Products Administration (NMPA) said inspections found that Sun Pharma’s quality management department failed to adequately fulfill its responsibilities during the production process. The company was cited for insufficient risk assessment of certain marketed batches that exceeded specification limits and for failing to take timely and effective corrective actions. The drug is used to treat patients in early and middle stages of Alzheimer's.
The Chinese regulator also identified deficiencies in contamination control and compliance with the Chinese pharmaceutical laws, concluding that the production process did not meet the requirements of China’s Good Manufacturing Practice for Pharmaceutical Products (2010 Revision).
The move underscores China’s tightening oversight of overseas pharmaceutical manufacturers supplying its domestic market, particularly in areas related to quality control and regulatory compliance.
Explore more exclusive insights at nextfin.ai.
Insights
What are the main regulatory requirements for pharmaceutical products in China?
What were the specific violations identified during Sun Pharma's inspection?
How does China's regulatory framework affect foreign pharmaceutical companies?
What impact has the ban on rivastigmine tartrate capsules had on the market?
What feedback have healthcare professionals provided regarding alternatives to Sun Pharma's drug?
What recent trends are emerging in China's pharmaceutical regulatory environment?
What are the latest updates on Sun Pharmaceutical Industries Limited’s response to the ban?
What long-term effects might stricter regulations have on pharmaceutical imports in China?
What challenges do foreign pharmaceutical companies face in complying with Chinese regulations?
How does the production process of Sun Pharma compare to other pharmaceutical manufacturers in China?
What similarities exist between this case and previous incidents involving foreign drug manufacturers in China?
What are the key factors contributing to the tightening oversight of pharmaceutical imports in China?
What are potential future developments in China's approach to pharmaceutical regulation?
What controversies surround the enforcement of pharmaceutical regulations in China?
How has public perception shifted regarding foreign pharmaceutical products in China?
What lessons can be learned from Sun Pharma's experience regarding quality control in pharmaceuticals?
What is the role of risk assessment in pharmaceutical manufacturing, as highlighted by this incident?
